MoonLake Immunotherapeutics超額配股權獲行使 額外集資3000萬美元

false
 0001821586
 
 
 
 
 
 
 
 0001821586
 
 
 2026-07-14
 2026-07-14
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 

 

 

UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

WASHINGTON,
D.C. 20549

 

FORM
8-K

 

CURRENT
REPORT

 

Pursuant
to Section 13 or 15(d)

of
the Securities Exchange Act of 1934

 

Date
of Report (Date of earliest event reported): July 14, 2026

 

MOONLAKE
IMMUNOTHERAPEUTICS

(Exact
Name of Registrant as Specified in Its Charter)

 

 
 Cayman
 Islands
  
 001-39630
  
 98-1711963

 
 (State
 or Other Jurisdiction

 of
 Incorporation)

  
 (Commission
 File Number)
  
 (IRS
 Employer 

Identification No.)

 
 

Dorfstrasse
29

6300
Zug

Switzerland

(Address
of principal executive offices and Zip Code)

 

41
415108022

(Registrant’s
Telephone Number, Including Area Code)

 

N/A

(Former
Name or Former Address, if Changed Since Last Report)

 

Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2 below):

 

 
 ☐
 Written
 communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 
  
  

 
 ☐
 Soliciting
 material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 
  
  

 
 ☐
 Pre-commencement
 communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 
  
  

 
 ☐
 Pre-commencement
 communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

Securities
registered pursuant to Section 12(b) of the Act:

 

 
 Title
 of each class
  
 Trading
 Symbol(s)
  
 Name
 of each exchange on which registered

 
 Class
 A ordinary share, par value $0.0001 per share
  
 MLTX
  
 The
 Nasdaq Capital Market

 
 

Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging
growth company ☐

 

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

  

 

 

Item
8.01. Other Events.

 

On
July 10, 2026, the underwriters of the previously announced public offering of Class A ordinary shares, par value $0.0001 per share (the
“Ordinary Shares”), of MoonLake Immunotherapeutics (the “Company”) and, in lieu of Ordinary Shares to certain
investors that so choose, pre-funded warrants to purchase Ordinary Shares, exercised in full their option (the “Option”)
to purchase an additional 1,500,000 Ordinary Shares (the “Option Shares”). As a result of the exercise of the Option, the
Company received additional gross proceeds of $30.0 million from the sale of the Option Shares, before deducting underwriting
discounts and commissions and offering expenses. The closing of the issuance and sale of the Option Shares occurred on July 14, 2026.

 

 1

  

 

 

SIGNATURE

 

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

 

 
  
 MOONLAKE
 IMMUNOTHERAPEUTICS

 
  
  

 
 Date: July 14, 2026
 By:
 /s/
 Matthias Bodenstedt                          

 
  
 Name: 
 Matthias
 Bodenstedt

 
  
 Title:
 Chief
 Financial Officer

 
 

 2